Axsome Therapeutics AXSM Balipodect — Eligible Milestone Payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept axsm:EligibleMilestonePayments.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
In the first quarter of 2026, the Company acquired the global rights to balipodect (AXS-20), a selective PDE10A Inhibitor for the treatment of Schizophrenia and other neuropsychiatric conditions, from Takeda Pharmaceutical Company Limited (Takeda), for $10.4 million, inclusive of transaction costs. Takeda is eligible to receive up to $260.0 million in development, regulatory and sales-based milestones and a mid single-digit royalty on potential global net sales of balipodect.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's balipodect — eligible milestone payments?
- Axsome Therapeutics (AXSM) reported balipodect — eligible milestone payments of $260M in Q1 2026.
- What does balipodect — eligible milestone payments mean?
- This reflects the potential future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial milestones related to the Balipodect program. These payments are typically contingent upon successful development phases or market approvals as defined in licensing or acquisition agreements. Monitoring these helps investors understand the future cash flow requirements and the risk-adjusted cost of advancing the program.
Ask your AI about Axsome Therapeutics's balipodect — eligible milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
